{
  "id": 5369502,
  "title": "Baird raises Climb Bio stock price target to $25 on trial data",
  "url": "https://urgent.news/2026/09/03/baird-raises-climb-bio-stock-price-target-to-25-on-trial-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T17:03:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/baird-raises-climb-bio-stock-price-target-to-25-on-trial-data-93CH-4888347"
  },
  "original_language": "en",
  "account": "Baird has increased its price target on Climb Bio (CLYM) stock to $25, up from $21, while keeping an Outperform rating. They highlight Phase 1 data for CLYM116, an anti-APRIL monoclonal antibody, demonstrating near-complete April suppression and decreased IgA and Gd-IgA1 in healthy volunteers. This profile is similar to earlier anti-APRILs but with a significantly longer half-life. Baird anticipates initial Phase 2 data to be available in the first half of 2027, with plans to launch a Phase 3 trial in 2027. They have raised their probability of success to 50% for this concept. Climb Bio recently announced positive Phase 1 trial results for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, which showed substantial APRIL and IgA suppression, with a drug half-life of approximately 29 days. This success has prompted H.C. Wainwright to also raise its price target for Climb Bio to $24, maintaining a Buy rating, and estimating a 30% chance of approval for CLYM116. Furthermore, Climb Bio has partnered with Beijing Mabworks Biotech to start a Phase 2 trial for IgA nephropathy in China, a significant step in their regional efforts. H.C. Wainwright also reiterated a $20 price target and a Buy rating on Climb Bio after presenting clinical data on another drug, budoprutug, at a medical conference. These updates demonstrate ongoing progress and interest in Climb Bio's pipeline.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Climb Bio slips after early-stage trial data for kidney disease drug",
        "url": "https://urgent.news/2026/09/03/climb-bio-slips-after-early-stage-trial-data-for-kidney-disease-drug",
        "published": "2026-09-03T16:11:38.000Z"
      },
      {
        "outlet": "Investing.com",
        "title": "BTIG raises Climb Bio stock price target to $32 on phase 1 data",
        "url": "https://urgent.news/2026/09/03/btig-raises-climb-bio-stock-price-target-to-32-on-phase-1-data",
        "published": "2026-09-03T18:06:56.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}